424 related articles for article (PubMed ID: 11948464)
1. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
[TBL] [Abstract][Full Text] [Related]
2. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
3. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
4. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
5. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
Int J Cancer; 1998 Oct; 78(2):202-8. PubMed ID: 9754653
[TBL] [Abstract][Full Text] [Related]
6. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Fisk B; Blevins TL; Wharton JT; Ioannides CG
J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
[TBL] [Abstract][Full Text] [Related]
7. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
8. Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.
Falk CS; Steinle A; Schendel DJ
J Exp Med; 1995 Oct; 182(4):1005-18. PubMed ID: 7561674
[TBL] [Abstract][Full Text] [Related]
9. In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.
Linehan DC; Peoples GE; Hess DT; Summerhayes IC; Parikh AS; Goedegebuure PS; Eberlein TJ
Surg Oncol; 1995 Feb; 4(1):41-9. PubMed ID: 7780612
[TBL] [Abstract][Full Text] [Related]
10. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
11. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines.
Schendel DJ; Gansbacher B; Oberneder R; Kriegmair M; Hofstetter A; Riethmüller G; Segurado OG
J Immunol; 1993 Oct; 151(8):4209-20. PubMed ID: 8409397
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
[TBL] [Abstract][Full Text] [Related]
14. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
15. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
[TBL] [Abstract][Full Text] [Related]
16. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
17. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
18. Characterization of T-cell receptor V beta repertoire in ovarian tumour-reacting CD3+ CD8+ CD4- CTL lines.
Fisk B; Flytzanis CN; Pollack MS; Wharton JT; Ioannides CG
Scand J Immunol; 1994 Dec; 40(6):591-600. PubMed ID: 7848491
[TBL] [Abstract][Full Text] [Related]
19. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo.
Gritzapis AD; Perez SA; Baxevanis CN; Papamichail M
Br J Cancer; 2005 Jan; 92(1):72-9. PubMed ID: 15583693
[TBL] [Abstract][Full Text] [Related]
20. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
